Auranofin Resistance in Toxoplasma gondii Decreases the Accumulation of Reactive Oxygen Species but Does Not Target Parasite Thioredoxin Reductase
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2021.618994
Abstract: Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, including Toxoplasma gondii. We generated auranofin… read more here.
Keywords: reactive oxygen; reductase; accumulation reactive; gondii ... See more keywords